The Binding Site unveils results of renal recovery study

The Binding Site, a firm that researches, develops and manufacturers immunodiagnostic assays, has announced the results of a recent pilot study it conducted on patients recovering from renal failure.

The research involved an assessment of standard chemotherapy with extended haemodialysis using a high cut-off dialyser (HCO-HD) on serum free light chain (FLC) concentrations and renal recovery.

It examined patients with biopsy-proven cast nephropathy and dialysis-dependent acute renal failure.

Overall, 13 out of 19 people who received uninterrupted chemotherapy and HCO-HD treatment showed a reduction in serum FLC concentration, as well as improving renal functions.

The Binding Site was established by researchers from the Medical School of Birmingham University in the early 70s as they aimed to discover innovative ways in which to produce antibodies.

Its annual turnover for the year ending September 2008 stood at 39.1 million pounds and the organisation employs around 460 individuals worldwide.